...
首页> 外文期刊>Clinical infectious diseases >Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: A systematic review and meta-analysis
【24h】

Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: A systematic review and meta-analysis

机译:社区获得性肺炎住院患者基于大环内酯类的治疗方案和死亡率:系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例

摘要

Background. Macrolides are used to treat pneumonia despite increasing antimicrobial resistance. However, the immunomodulatory properties of macrolides may have a favorable effect on pneumonia outcomes. Therefore, we systematically reviewed all studies of macrolide use and mortality among patients hospitalized with community-acquired pneumonia (CAP).Methods.All randomized control trials (RCTs) and observational studies comparing macrolides to other treatment regimens in adults hospitalized with CAP were identified through electronic databases and gray literature searches. Primary analysis examined any macrolide use and mortality; secondary analysis compared Infectious Diseases Society of America/American Thoracic Society guideline-concordant macrolide/beta-lactam combinations vs respiratory fluoroquinolones. Random effects models were used to generate pooled risk ratios (RRs) and evaluate heterogeneity (I 2).Results.We included 23 studies and 137 574 patients. Overall, macrolide use was associated with a statistically significant mortality reduction compared with nonmacrolide use (3.7 [1738 of 47 071] vs 6.5 [5861 of 90 503]; RR, 0.78; 95 confidence interval [CI],. 64-.95; P =. 01; I 2= 85). There was no survival advantage and heterogeneity was reduced when analyses were restricted to RCTs (4.6 [22 of 479] vs 4.1 [25 of 613]; RR, 1.13; 95 CI,. 65-1.98; P =. 66; I 2= 0) or to patients treated with guideline-concordant antibiotics (macrolide/beta-lactam, 5.3 [297 of 5574] vs respiratory fluoroquinolones, 5.8 [408 of 7050]; RR, 1.17; 95 CI,. 91-1.50; P =. 22; I 2= 43). Conclusions. In hospitalized patients with CAP, macrolide-based regimens were associated with a significant 22 reduction in mortality compared with nonmacrolides; however, this benefit did not extend to patients studied in RCTs or patients that received guideline-concordant antibiotics. Our findings suggest guideline concordance is more important than choice of antibiotic when treating CAP.
机译:背景。大环内酯类药物尽管抗药性增强但仍可用于治疗肺炎。然而,大环内酯类的免疫调节特性可能对肺炎的结局具有有利的影响。因此,我们系统地回顾了所有社区获得性肺炎(CAP)住院患者中大环内酯类药物的使用和死亡率的所有研究。方法。通过以下方法,我们比较了通过CAP住院的成年人对大环内酯类药物与其他治疗方案进行比较的所有随机对照试验(RCT)和观察性研究。电子数据库和灰色文献搜索。初步分析检查了大环内酯类药物的使用和死亡率。二级分析比较了美国传染病学会/美国胸科学会指南一致的大环内酯/β-内酰胺组合与呼吸道氟喹诺酮类药物的比较。结果采用随机效应模型产生合并风险比(RRs)并评估异质性(I 2)。结果我们纳入了23项研究和137 574例患者。总体而言,与非大环内酯类药物相比,大环内酯类药物的使用具有统计学上的显着降低死亡率(3.7 [4701的1738]与6.5 [90503的586]; RR 0.78; 95置信区间[CI],64-.95; P = .01; I 2 = 85)。当分析仅限于RCT时,没有生存优势,异质性降低(4.6 [479的22] vs 4.1 [613的25]; RR,1.13; 95 CI,65-1.98; P =。66; I 2 = 0)或接受指导性一致抗生素治疗的患者(大环内酯/β-内酰胺,5.3 [297,5574]与呼吸性氟喹诺酮类药物,5.8 [70,408的比例]; RR,1.17; 95 CI,91-1.50; P =。 22; I 2 = 43)。结论在住院的CAP患者中,基于大环内酯类药物的治疗方案与非大环内酯类药物相比,可使死亡率显着降低22。但是,这种益处并未扩展到接受RCT研究的患者或接受符合指南要求的抗生素的患者。我们的研究结果表明,治疗CAP时,指南一致性比选择抗生素更重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号